PARP1 and neoplasm: When looking at the efficacies of these three PARP inhibitors in specific pediatric (ES (n = 19), NB (n = 23), MB (n = 4), RMS (n = 7) and OS (n = 10)) and adult (n = 686) tumor cell lines, we observed a range of sensitivities.